Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Aug 07, 2026
GraniteShares 2x Long BABA Daily ETF (BABX) +43% in 30 Days: Recovery in Focus

GraniteShares 2x Long BABA Daily ETF (BABX) +43% in 30 Days: Recovery in Focus

Key Takeaways

  • BABX surged approximately 43% over the past 30 days, driven by a sharp recovery in Alibaba Group Holding Limited (BABA) ADR shares from deeply oversold levels.
  • Over the last quarter, BABX declined roughly 26%, reflecting the leveraged impact of BABA's prolonged selloff through May and June before the recent rebound took hold.
  • The primary catalyst was a powerful relief rally in Chinese technology equities, fueled by improving AI sentiment, easing interest rate expectations, and news that Alibaba's Qwen AI model received Chinese regulatory approval for integration into Apple Intelligence features in China.
  • As a 2x daily leveraged single-stock ETF, BABX amplifies both gains and losses in BABA, making it highly sensitive to swings in the underlying ADR and unsuitable for buy-and-hold investors.
  • Risks remain elevated: Alibaba faces ongoing Pentagon blacklist designation, negative free cash flow from heavy AI infrastructure spending, and unresolved shareholder litigation.

GraniteShares 2x Long BABA Daily ETF (BABX) Overview and Portfolio Exposure

The GraniteShares 2x Long BABA Daily ETF (BABX) is an actively managed leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, of 2 times (200%) the daily percentage change in the American Depositary Receipt (ADR) of Alibaba Group Holding Limited, which trades on the NYSE under the ticker BABA. The fund was launched in December 2022 and carries a net expense ratio of 1.15%.

Unlike diversified ETFs that hold baskets of securities, BABX is a single-stock leveraged product. It achieves its 2x daily objective primarily through swap agreements and options on BABA, supplemented by direct ownership of the underlying ADR. The fund is non-diversified and is designed exclusively for sophisticated traders who understand the effects of daily compounding, leverage decay, and volatility drag. The fund's assets under management (AUM) stood at approximately $74.5 million as of late June 2026. When reviewing exposure details, I checked comparable single-stock products using Tickeron’s AI Screener to gauge relative volatility profiles.

Because BABX's entire exposure is linked to a single company, every percentage move in BABA is magnified twofold on a daily basis—making portfolio-level diversification analysis less relevant than understanding Alibaba's business segments: Core Commerce (Taobao, Tmall, Alibaba.com), Cloud Intelligence, Digital Media and Entertainment, and Innovation Initiatives. When BABA shares experience sharp directional moves, BABX amplifies those swings dramatically in both directions.

GraniteShares 2x Long BABA Daily ETF (BABX) Price Performance: Last 30 Days vs. Quarter

Over the 30-day period ending July 30, 2026, BABX surged approximately 43%, climbing from $13.86 to $19.82. This explosive move represented a powerful recovery from deeply depressed levels after the fund had fallen to multi-month lows in late June. The rally was not linear—intra-period volatility remained elevated, with daily swings of 5% to 10% occurring frequently as BABA itself experienced wide trading ranges.

The quarterly picture tells a starkly different story. Over the approximately 90-day period from late April through late July, BABX declined roughly 26%, falling from around $26.81 to $19.82. This decline reflects the leveraged compounding effect of BABA's sustained drawdown during May and June, when the underlying ADR lost more than 25% of its value amid a confluence of negative headlines. The asymmetric return profile—a steep quarterly loss followed by a sharp 30-day rebound—exemplifies the extreme volatility inherent in daily leveraged single-stock ETFs. I also verified the price data points against broader sector moves via Tickeron’s AI Daily Buy/Sell Signals to confirm the timing of the inflection.

What Drove BABX Price in the Last 30 Days

The 30-day surge in BABX was almost entirely a function of BABA's powerful recovery from its late-June lows. The underlying ADR rebounded from approximately $92–$96 in the final week of June to above $116 by late July—a gain of more than 20% that the 2x leveraged fund magnified.

Several catalysts drove the turnaround. First, Chinese regulators approved the integration of Alibaba's Qwen AI model into Apple Intelligence features for the China market, marking a significant validation of Alibaba's AI capabilities and opening a major distribution channel. Second, Microsoft's strong fiscal fourth-quarter earnings—featuring Azure revenue growth of 43% year-over-year—lifted global cloud and AI sentiment, and Alibaba Cloud, which had been accelerating to approximately 38–40% revenue growth with AI-related products contributing roughly 30% of external cloud revenues, benefited from the halo effect. Third, declining expectations for further Federal Reserve interest rate hikes improved risk appetite for emerging-market and Chinese technology equities.

Morgan Stanley reiterated BABA as a top pick in early July, citing Alibaba's position as the largest cloud infrastructure provider in China and expected market share gains during the AI cycle. Multiple Wall Street analysts maintained buy ratings with price targets implying 50–60% upside from July levels. This institutional support, combined with deeply oversold technical conditions, created a potent environment for the sharp rebound that BABX amplified.

What Drove BABX Performance Over the Last Quarter

The quarterly decline of approximately 26% in BABX was driven by a punishing selloff in BABA that intensified from mid-May through late June. The downturn was triggered by Alibaba's fiscal fourth-quarter 2026 earnings report on May 13, which revealed an operating loss—the company's first since early 2021—and a collapse in adjusted EBITA of 84% year-over-year. Although revenue grew 3%, heavy spending on AI infrastructure, cloud capacity, and quick-commerce initiatives pushed free cash flow deeply into negative territory, raising concerns about capital allocation and future profitability.

The selloff accelerated in early June when the U.S. Department of Defense added Alibaba to its list of Chinese military-linked companies, compounding geopolitical risk. Cathie Wood's ARK Invest liquidated nearly its entire BABA position in June, adding to selling pressure. China's 618 shopping festival produced underwhelming sales figures, and several analyst firms—including Daiwa, HSBC, and Morgan Stanley—cut their BABA price targets. By June 25–26, BABA had fallen to approximately $92–$95, its lowest level in over a year. BABX, with its 2x daily leverage, was disproportionately hit during this cascade of negative catalysts, exacerbated by the compounding effects of volatile downward daily moves.

BABX ETF Outlook: What Investors Should Watch Next

Looking ahead, BABX's trajectory will remain tightly coupled to BABA's price action, and several factors warrant close attention. On the positive side, Alibaba's Cloud Intelligence segment is accelerating, with AI-related revenues expected to surpass 50% of external cloud revenue within approximately 12 months. The Qwen AI model's integration into Apple's China ecosystem could unlock a substantial new revenue stream. Additionally, Alibaba's balance sheet remains strong, with over RMB520 billion in cash and liquid investments providing a buffer against continued negative free cash flow.

On the risk side, Alibaba's capital expenditure is expected to overshoot its original RMB380 billion target as AI infrastructure needs expand, potentially prolonging cash flow weakness. The Pentagon's blacklist designation remains in force and could restrict procurement-related business. A €550 million European Commission fine against AliExpress for Digital Services Act violations adds regulatory uncertainty. Alibaba's upcoming fiscal first-quarter 2027 earnings report in late August will be a critical event: consensus estimates point to approximately $1.94 in earnings per share (EPS), and any deviation could trigger outsized moves in BABX given the 2x leverage structure.

Macroeconomic factors—including U.S.-China trade relations, Federal Reserve monetary policy, and the pace of global AI adoption—will continue to shape sentiment toward Chinese technology equities. For traders using BABX, the essential consideration remains that daily resetting leverage magnifies both opportunity and risk. Holding periods beyond a single trading day introduce compounding effects that can cause returns to deviate materially from 2x the underlying stock's cumulative performance, particularly in volatile, range-bound, or trending-lower markets.

Using Tickeron AI Tools in My Research

When evaluating high-volatility products like BABX, I regularly rely on Tickeron’s AI Screener to scan for momentum shifts, technical patterns, and volatility signals across the market. The platform helps surface relevant data points quickly and supports more informed timing decisions around leveraged instruments. It has become a practical part of my workflow for monitoring names tied to single-stock ETFs and sector rotation themes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BABX

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


BABX in upward trend: 10-day moving average crossed above 50-day moving average on July 31, 2026

The 10-day moving average for BABX crossed bullishly above the 50-day moving average on July 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on BABX as a result. In of 56 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BABX just turned positive on July 06, 2026. Looking at past instances where BABX's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .

BABX moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BABX advanced for three days, in of 182 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 90 cases where BABX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BABX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BABX broke above its upper Bollinger Band on July 31, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks the fund seeks daily investment results, before fees and expenses, of 2 times (200%) the daily percentage change of the ADR of Alibaba Group Holding Limited (NYSE: BABA). The fund is an actively managed exchange traded fund that attempts to replicate 2 times (200%) the daily percentage change of the underlying stock by entering financial instruments such as swaps and options on the underlying stock as well as directly purchasing the underlying stock. It is non-diversified.
View a ticker or compare two or three
BABX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
GraniteShares ETF Trust30 Vesey Street, 9th FloorNew York
Phone
N/A
Web
N/A
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.